Bagdasarian A, Tonetta S, Harel W, Mamidi R, Uemura Y
Alpha Therapeutic Corporation, R&D Department, Los Angeles, CA 90032, USA.
Vox Sang. 1998;74(2):74-82.
A clinical study was conducted to determine the effect of IVIG infusion rates on adverse experiences (AE) and on serum levels of cytokines and vasoactive substances.
Forty-two healthy volunteers were randomized into 3 groups with maximum IVIG infusion rates of 0.04, 0.06, and 0.08 ml/kg/min, and a final dose of 0.5 g IgG/kg body weight.
Adverse reactions were noted only at the highest infusion rate of 0.08 ml/kg/min, except in 1 subject infused at 0.06 ml/kg/min. There were significant increases in IL-6 (p = 0.011) and thromboxane B2 (p = 0.007) in AE subjects as compared to non-AE subjects.
IVIG-induced adverse reactions occur more often with rapid infusion rates and may be mediated by elevated levels of inflammatory cytokines and vasoactive substances.
开展一项临床研究以确定静脉注射免疫球蛋白(IVIG)的输注速率对不良事件(AE)以及细胞因子和血管活性物质血清水平的影响。
42名健康志愿者被随机分为3组,最大IVIG输注速率分别为0.04、0.06和0.08毫升/千克/分钟,最终剂量为0.5克免疫球蛋白G/千克体重。
仅在最高输注速率0.08毫升/千克/分钟时出现不良反应,有1名以0.06毫升/千克/分钟输注的受试者除外。与非AE受试者相比,AE受试者的白细胞介素-6(IL-6,p = 0.011)和血栓素B2(p = 0.007)显著升高。
IVIG诱导的不良反应在快速输注速率时更常发生,可能由炎症细胞因子和血管活性物质水平升高介导。